Pharmaceutical products development veteran Jørgen Wittendorff has been appointed as head of manufacturing at Silence Therapeutics PLC (LON:SLN).
He will be responsible for the process development and manufacturing of siRNA (silencing ribonucleic acid) therapeutic products for clinical trials and, ultimately, commercial use.
Wittendorff has more than 25 years of experience in the industry, having previously been a senior director at CMC manufacturing and product supply at Ablynx and also having held senior positions at Ferring Pharmaceuticals and Novo Nordisk.
“Jørgen's extensive experience in complex manufacturing from Ablynx will be a significant contribution to Silence,” said David Horn Solomon, the chief executive officer of Silence.
“In his new role, Jørgen will be able to critically contribute to the manufacturing efforts to progress Silence's three significant sets of assets in gene silencing siRNA: SLN124, for the treatment of iron overload disorders, SL360, for the treatment of cardiovascular disease, and SL500 with partner Mallinckrodt Pharmaceuticals, for the treatment of complement-mediated disorders," he added.